Esther Rajavelu - 01 Feb 2024 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Role
Chief Financial Officer and Chief Business Officer
Signature
/s/ Tamara Joseph, Attorney-in-Fact for Esther Rajavelu
Issuer symbol
SPRO
Transactions as of
01 Feb 2024
Net transactions value
$0
Form type
4
Filing time
05 Feb 2024, 20:44:28 UTC
Previous filing
15 Nov 2023
Next filing
12 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Award $0 +119,866 +40% $0.000000 419,866 01 Feb 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2025, subject to the Reporting Person's continued service through the applicable vesting date.

Remarks:

Chief Financial Officer and Chief Business Officer